洛铂联合方案治疗晚期乳腺癌的临床研究

目的探讨洛铂联合化疗方案在治疗晚期乳腺癌中的疗效与不良反应。方法收集2012年1月至2014年12月共52例晚期乳腺癌患者,予以洛铂联合化疗方案治疗,21~28d为1个周期。所有患者至少完成2个周期治疗,之后评价疗效及不良反应。结果无1例达到完全缓解(CR),部分缓解(PR)16例,疾病稳定(SD)21例,疾病进展(PD)15例,有效率(RR)为30.8%,疾病控制率(DCR)为71.2%。雌激素受体(ER)或人类表皮生长因子2(HER-2)阳性表达者与阴性表达者比较,RR差异均无统计学意义(P0.05)。一线治疗者与二线及以上治疗者比较,RR差异有统计学意义(P0.05)。三阴性乳腺癌患者中,乳腺癌易感基因1(BRCA1)突变者与BRCA1无突变者的DCR比较,差异有统计学意义(P0.05)。无内脏转移患者RR高于有内脏转移患者,差异有统计学意义(P0.05)。至随访日期止,46例患者为PD,中位疾病进展时间为6.5个月(95%置信区间为5.2~7.8个月)。主要不良反应为骨髓抑制、胃肠道反应等,多为0~Ⅱ度,经对症处理后可缓解,无治疗相关性死亡。结论洛铂联合化疗方案治疗晚期乳腺癌疗效较好,不良反应均可耐受。

Clinical study of chemotherapy contains Lobaplatin in treating advanced breast cancer

Objective To observe the efficacy and adverse reactions of chemotherapy regimens containing Lobaplatin in treat-ment of advanced breast cancer .Methods From January 2012 to December 2014 ,a total of 52 cases of advanced breast cancer were collected ,who accepted Lobaplatin-containing chemotherapy regimens ,21 - 28 days as a cycle .All patients completed at least two cycles and then the efficacy and adverse reactions were evaluated .Results No case obtained complete remission(CR) ,16 patients a-chieved part remission(PR) ,21 patients achieved stable disease(SD) ,15 patients achieved disease progression(PD) .The response rate was 30 .8% ,and the disease control rate was 71 .2% .There were no significant differences on the response rate among patients with negative and positive results of estrogen receptors(ER)and human epidermal growth factor receptor-2(HER-2)(P > 0 .05) . The significant difference was found on RR between the first-line treatment and second-line treatment (P < 0 .05) .Among triple negative breast cancer patients ,Stratification analysis by BRCA1 status ,there was significant difference of DCR between negative and positive BRCA1 patients(P < 0 .05) .The significant difference was found on RR between no visceral metastasis and visceral metastases patients(P< 0 .05) .Follow-up to the deadline ,the disease of 46 patients had progressed ,the median time of progression was 6 .5 months(95% CI :5 .2 - 7 .8 months) .The main side effects were myelosuppression ,gastrointestinal reactions ,which were mostly in degree 0 - Ⅱ ,and alleviated by symptomatic treatment .No treatment-related deaths occurred .Conclusion Lobaplatin-contained regimens has a significant antitumor effect to advanced breast cancer with manageable toxicities .